Balwinder Singh, MD, MS

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota

  • 12Articles
  • 206.7KReads
  • 2016–2026Active
  • 39Collaborators
  • 201Citations

About

Balwinder Singh, MD, MS, is affiliated with the Department of Psychiatry and Psychology at Mayo Clinic in Rochester, Minnesota. Singh has published extensively on topics including major depressive disorder, treatment-resistant depression, addiction, anxiety, posttraumatic stress disorder, psychedelics, psychopharmacology, psychotherapy, and suicide. The work encompasses clinical studies and reviews on interventions such as ketamine, esketamine, lithium augmentation, selective serotonin reuptake inhibitors, thyroid hormone use, and adjunctive aripiprazole, as well as nonpharmacologic treatments like exercise, yoga, and tai chi. Singh's research has appeared in Psychiatrist.com from 2016 to 2026.

Publications

JCP
Psychotherapy, Pharmacotherapy, and Neuromodulatory Interventions in Operational Definitions of TRD: Reply to De Oliveira Reis et al
Letter to the Editor

Psychotherapy, Pharmacotherapy, and Neuromodulatory Interventions in Operational Definitions of TRD: Reply to De Oliveira Reis et al

August 19, 2026

Marques et al reply to commentary on their consensus-based recommendations for treatment-resistant depression.
, ,
JCP
Next-Step Treatment Options for Treatment-Resistant Depression
Consensus Statement

Next-Step Treatment Options for Treatment-Resistant Depression

January 21, 2026

Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
, , , et al
JCP
Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression
Original Research

Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression

September 17, 2025

After the acute phase of ketamine treatment, ED visits for suicidal ideation decreased by 84%, and total ED visits for suicidality decreased by 63%.
, , , et al
JCP
Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression
Original Research

Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression

July 30, 2025

The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.
, , , et al
JCP
SSRI Discontinuation and AUD Relapse
Case Report

SSRI Discontinuation and AUD Relapse

August 26, 2024

A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to...
, , , et al
JCP
When and How to Use Lithium Augmentation for MDD
ASCP Corner

When and How to Use Lithium Augmentation for MDD

March 8, 2023

With its antisuicidal effect and low cost, lithium can be an effective alternative to other MDD augmentation strategies when antidepressants are not enough.
, ,
JCP
Ketamine vs Esketamine for TRD
Original Research

Ketamine vs Esketamine for TRD

February 1, 2023

Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.
, , , et al
JCP
Thyroid Hormone Use in Mood Disorders
ASCP Corner

Thyroid Hormone Use in Mood Disorders

August 15, 2022

This ASCP Corner article reviews the potential benefits and harms of thyroid hormone therapy in the management of unipolar and bipolar depression.
,
PCC
Meta-Analysis

Adjunctive Aripiprazole for MDD

June 24, 2021

Given the scarcity of data, the authors of this review systematically synthesized the literature to determine the long-term efficacy and safety of aripiprazole as a maintenance augmenting agent for...
, , , et al
PCC
Review Article

Exercise, Yoga, and Tai Chi for Depression

December 31, 2020

Exercise, yoga, and tai chi are commonly used complementary approaches for health and wellness. This review aims to synthesize the evidence for exercise, yoga, and tai chi in the...
, , , et al
JCP
Letter to the Editor

BMI and Remission in Depressed Patients Receiving IV Ketamine

November 12, 2019

Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...
, , , et al
PCC
Article

Efficacy of Prazosin in PTSD

July 28, 2016

Prazosin is an emerging treatment modality for the debilitating symptoms of PTSD. But, while the evidence of its effectiveness and efficacy is promising, it is not definitive. The authors...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe